ERBB2 and breast carcinoma: Therefore, targeting HER3 may alleviate anti‐HER2 therapy resistance in breast cancer; however, this approach appears to be extremely challenging despite the extensive preclinical and clinical efforts due to HER3 containing a pseudokinase domain in its intracellular region which renders it undruggable with kinase inhibitors [10, 11].